Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...
Takeda Pharmaceutical Co.: Hold Rating Amid Mixed Q3 Results, Upward Guidance Revision, and Strategic Moves
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Management View Christophe Weber, CEO, announced his retirement ...
BioSpace20h
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...
Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript
Takeda Pharmaceutical Company Limited ( NYSE: TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Christopher O’Reilly - Head, Investor Relations Christophe Weber - President and Chief ...